EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib

Selection of Patients with Hepatocellular Carcinoma for Sorafenib

(2017) Ghassan K. Abou-Alfa   Journal of the National Comprehensive Cancer Network

Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study

(2011) C. Gridelli et al.   ANNALS OF ONCOLOGY

Skin Tumors Induced by Sorafenib; Paradoxic RAS-RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1

(2011) J. P. Arnault et al.   CLINICAL CANCER RESEARCH

Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer

(2011) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

Hepatocellular Carcinoma

(2011) Hashem B. El-Serag   NEW ENGLAND JOURNAL OF MEDICINE

Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy

(2010) Augusto Villanueva et al.   Annual Review of Medicine

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

Synergistic role of sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis

(2010) Susie A. Lee et al.   HEPATOLOGY

BAD, a Proapoptotic Member of the BCL2 Family, Is a Potential Therapeutic Target in Hepatocellular Carcinoma

(2010) A. Galmiche et al.   MOLECULAR CANCER RESEARCH

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

The landscape of somatic copy-number alteration across human cancers

(2010) Rameen Beroukhim et al.   NATURE

AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC)

(2009) Hung Huynh et al.   JOURNAL OF HEPATOLOGY

Epidermal Growth Factor Receptor Expression and Gene Copy Number in Conventional Hepatocellular Carcinoma

(2008) Anne F. Buckley et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE